Tyrosine kinase fusion genes in chronic myeloproliferative diseases

Leukemia

Volumn 16, Issue 7, 2002, Pages 1207-1212

  Cross, N C P ^a   Reiter, A ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ABL; FGFR1; JAK2; Myeloproliferative disorders; PDGFRB; Tyrosine kinase

Indexed keywords

BCR ABL PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HYBRID PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE;

ADULT; ANEUPLOIDY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; DIAGNOSTIC ACCURACY; FEMALE; FUSION GENE; GENE DISRUPTION; HEMATOPOIESIS; HUMAN; HUMAN CELL; KARYOTYPE; MALE; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECIPROCAL CHROMOSOME TRANSLOCATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0036045381     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402556     Document Type: Review

References (60)

1. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997
2. Chronic myeloid leukemia
3. The molecular biology of chronic myeloid leukemia
4. Cytogenetics of chronic myeloid leukaemia
5. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
6. Haematological classification of the chronic myeloid leukaemias
7. BCR rearrangement-negative chronic myelogenous leukemia revisited
8. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: A review
9. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): Description of a distinctive clinicopathologic entity
10. The 8p11 myeloproliferative syndrome: A distinct clinical entity caused by constitutive activation of FGFR1
11. Myeloproliferative disorders with translocations of chromosome 5q31-35: Role of the platelet-derived growth factor receptor beta
12. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome
13. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)
14. The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP
15. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome
16. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1
17. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33)
18. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: Transforming activity and specific inhibition of FGFR1 fusion proteins
19. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: The first fusion gene involving BCR but not ABL
20. The 8p12 myeloproliferative disorder. t(8;19)(p12;q13.3): A novel translocation involving the FGFR1 gene
21. Identification of four new translocations involving FGFR1 in myeloid disorders
22. 8p12 stem cell myeloproliferative disorder: The FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and 3-kinase/Akt/mTOR pathways
23. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
24. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2)
25. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21)
26. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22)
27. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia
28. Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution
29. Receptor signaling: When dimerization is not enough
30. The ins and outs of fibroblast growth factors
31. Cellular distribution of platelet-derived growth factor, transforming growth factor-beta, basic fibroblast growth factor, and their receptors in normal bone marrow
32. Signal transduction via platelet-derived growth factor receptors
33. ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5
34. TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: A common mechanism for transformation by tyrosine kinase fusion proteins
35. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways
36. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins
37. Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation
38. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: A novel regulatory mechanism for tyrosine kinase signaling
39. Transforming properties of the Huntingin interacting protein 1/platelet-derived growth factor beta receptor fusion protein
40. STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation
41. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581
42. The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways
43. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion
44. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia
45. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo-and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes
46. A novel BCR-JAK2 fusion gene is the result of a translocation (9;22)(p24;q11) in a case of CML
47. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12)
48. Cytogenetic peculiarities in chronic myelogenous leukemia
49. Chronic myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98/HOXA9 fusion
50. Ph-negative chronic myelocytic leukemia with a complex translocation involving chromosomes 7 and 11
51. The translocation (6;9) (p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features
52. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9
53. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia
54. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
55. Roots of clinical resistance to STI-571 cancer therapy
56. Roots of clinical resistance to STI-571 cancer therapy
57. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
58. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336
59. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
60. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial